AZ rejigs endpoints in key trial of durvalumab
About Richard Staines
Posts by Richard Staines:
Health systems should fund more treatments for chronic diseases, says EFPIA
2017 could be a bumper year for M&A – but Trump’s price control threats dominate
Review extended by three months.
Patients could be denied treatments, says BIA
Samsung to take on patent thicket surrounding Humira.
Industry giants such as AstraZeneca and Novartis are on board.
Afinitor finally recommended after rejection in 2011.